Fekra Therapeutics Company Profile, Contacts & Intelligence

Fekra Therapeutics Overview

Fekra Therapeutics is a clinical stage biotech company focused on developing novel first-in-class small-molecule cancer therapeutics. Fekra's lead program is FK-01, an oral BMX non-receptor tyrosine kinase inhibitor with proposed indication for metastatic/non-metastatic Castration-Resistant Prostate Cancer (m/non-mCRPC). Why? Well, Hormonal Therapy ( i.e. Androgen Deprivation Therapy, ADT) is still the mainstay treatment option for patients with progressive prostate cancer. Unfortunately, patients eventually develop resistance to these therapies. Interestingly, the target of interest BMX was found to be overexpressed in response to ADT and contributed to such resistance. Fekra with its FK-01 lead program aims to develop a new and novel therapeutic paradigm for patients with such devastating and progressive cancer.

Headquarters

6 Liberty Sq

Website

fekratx.com

Industry

Biotechnology Research

Founded

2020

NAICS

Research and Development in Biotechnology (except Nanobiotechnology)

Fekra Therapeutics Contact Intelligence

See which contact channels and departments are represented in the visible AeroLeads data.

Fekra Therapeutics People & Org Chart Preview

Sample people records show job titles and whether email or phone data is available without exposing raw contact details.

Compare Similar Companies to Fekra Therapeutics

Explore companies in related markets and compare their industry and employee estimates.